The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...

European regulators have recommended Johnson & Johnson’s Zytiga prostate cancer drug in a key new use earlier in the disease, which could see it gain traction against Pfizer’s rival ...